[go: up one dir, main page]

MX2013001279A - Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral. - Google Patents

Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.

Info

Publication number
MX2013001279A
MX2013001279A MX2013001279A MX2013001279A MX2013001279A MX 2013001279 A MX2013001279 A MX 2013001279A MX 2013001279 A MX2013001279 A MX 2013001279A MX 2013001279 A MX2013001279 A MX 2013001279A MX 2013001279 A MX2013001279 A MX 2013001279A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
phosphodiesterase inhibitor
selective enzyme
gel form
enzyme phosphodiesterase
Prior art date
Application number
MX2013001279A
Other languages
English (en)
Inventor
Miguel Angel Garcia Perez
Gabriel Marcelin Jimenez
Concepcion Albina Vazquez Flores
Alionka Citlali P Angeles Moreno
Octavio Caro Rodriguez
Ricardo David Avila Cedillo
Original Assignee
Miguel Angel Garcia Perez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miguel Angel Garcia Perez filed Critical Miguel Angel Garcia Perez
Priority to MX2013001279A priority Critical patent/MX2013001279A/es
Publication of MX2013001279A publication Critical patent/MX2013001279A/es
Priority to PCT/MX2014/000028 priority patent/WO2014119985A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una novedosa composición farmacéutica para administración oral en forma de líquido y/o semisólido de liberación modificada que contiene una cantidad efectiva terapéuticamente de al menos un agente inhibidor selectivo de la enzima fosfodiesterasa y/o sus sales farmacéuticamente aceptables, en combinación con uno o más solventes y/o co-solventes y/o uno más excipientes farmacéuticamente aceptables. Mediante la novedosa composición desarrollada en la presente invención, se alcanzan concentraciones plasmáticas máximas por mayor tiempo, es decir, la liberación y absorción de sildenafil mediante la administración de la novedosa composición se lleva a cabo de manera sostenida con una absorción de forma paulatina.
MX2013001279A 2013-01-31 2013-01-31 Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral. MX2013001279A (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2013001279A MX2013001279A (es) 2013-01-31 2013-01-31 Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
PCT/MX2014/000028 WO2014119985A2 (es) 2013-01-31 2014-01-28 Composición farmacéutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2013001279A MX2013001279A (es) 2013-01-31 2013-01-31 Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.

Publications (1)

Publication Number Publication Date
MX2013001279A true MX2013001279A (es) 2013-08-26

Family

ID=49552933

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001279A MX2013001279A (es) 2013-01-31 2013-01-31 Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.

Country Status (2)

Country Link
MX (1) MX2013001279A (es)
WO (1) WO2014119985A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2584248A1 (es) * 2015-03-24 2016-09-26 Farmalider, S.A. Composición farmacéutica de citrato de sildenafilo en forma de suspensión para uso oral

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2649834C1 (ru) * 2016-07-06 2018-04-04 Фармалидер С.А. Фармацевтическая композиция силденафила цитрата в форме суспензии для перорального применения
US11534493B2 (en) * 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
CN112587476B (zh) * 2020-12-23 2022-09-27 无锡市妇幼保健院 一种适用于新生儿动脉高压的西地那非啫喱新剂型及其制备方法
CN113577079B (zh) * 2021-07-28 2022-08-23 山东裕欣药业有限公司 一种磷酸二酯酶抑制剂的制备方法及组合物
PL247528B1 (pl) * 2023-04-08 2025-07-21 Sativa Med Spolka Akcyjna Płynna kompozycja inhibitorów fosfodiesterazy typu 5 (PDE-5), sposób jej wytwarzania oraz jej zastosowanie do leczenia zaburzeń erekcji

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060353A1 (en) * 2000-02-21 2001-08-23 Fujisawa Pharmaceutical Co., Ltd. Liquid preparation with improved absorbability
JP5686978B2 (ja) * 2009-03-18 2015-03-18 第一三共ヘルスケア株式会社 シルデナフィルクエン酸塩含有内服液剤及びその液剤含有容器
DE102009033396A1 (de) * 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
CN102204917B (zh) * 2011-03-30 2013-10-09 天津红日药业股份有限公司 一种含有法舒地尔与西地那非的药物组合物及其制备方法和用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2584248A1 (es) * 2015-03-24 2016-09-26 Farmalider, S.A. Composición farmacéutica de citrato de sildenafilo en forma de suspensión para uso oral

Also Published As

Publication number Publication date
WO2014119985A3 (es) 2014-11-27
WO2014119985A2 (es) 2014-08-07

Similar Documents

Publication Publication Date Title
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
MX2020003415A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
CY1120832T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
BR112017007662A8 (pt) Composto, composição farmacêutica e uso de um composto
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
PH12016500024A1 (en) Bromodomain inhibitor
EA201591751A1 (ru) Трипептидные эпоксикетонные ингибиторы протеазы
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
AR091876A1 (es) Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
BR112018015718A2 (pt) utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash)
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
MX383254B (es) Combinacion que comprende un glucocorticoide y edo-s101.
EA201692276A1 (ru) Комбинации тиотропия бромида, формотерола и будесонида для лечения хобл
AR086800A1 (es) Composicion farmaceutica oftalmologica topica que contiene regorafenib
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
EA201491870A1 (ru) Способ лечения гиперурикемии у больных подагрой с помощью галофената или галофеновой кислоты и противовоспалительного агента
MX378409B (es) Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa.

Legal Events

Date Code Title Description
FG Grant or registration